Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
These alerts are based on real patient cases involving serious health consequences
These findings highlight a critical window for secondary prevention and demonstrate how large-scale real-world data can surface clinically meaningful risk patterns beyond what trials or registries alone can capture
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Ozempic) and chronic weight management (Wegovy)
(Notably, tirzepatide in diabetics also lowers HbA1c, and even though the OSA trial excluded diabetics, the drugs metabolic effects would likely benefit prediabetic OSA patients by improving glycemic control.) This multifaceted impact can be viewed as a holistic approach to a cardiometabolic syndrome, where OSA is one piece of the puzzle
US$ 28.43
US$ 22.62
US$ 20.07
US$ 20.25
US$ 22.04
US$ 29.05
US$ 26.34
US$ 20.03
US$ 20.65
